Dare Bioscience Inc (DARE)
0.4349
-0.01
(-3.31%)
USD |
NASDAQ |
Jun 17, 16:00
0.43
0.00 (0.00%)
Pre-Market: 20:00
Dare Bioscience Free Cash Flow: -30.19M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -30.19M |
| December 31, 2023 | -39.49M |
| September 30, 2023 | -36.60M |
| June 30, 2023 | -20.06M |
| March 31, 2023 | -21.92M |
| December 31, 2022 | -18.15M |
| September 30, 2022 | -22.17M |
| June 30, 2022 | -29.41M |
| March 31, 2022 | -32.75M |
| December 31, 2021 | -28.78M |
| September 30, 2021 | -28.06M |
| June 30, 2021 | -34.72M |
| March 31, 2021 | -27.03M |
| December 31, 2020 | -25.25M |
| September 30, 2020 | -19.87M |
| June 30, 2020 | -17.69M |
| March 31, 2020 | -16.60M |
| December 31, 2019 | -13.32M |
| September 30, 2019 | -12.22M |
| June 30, 2019 | -11.79M |
| March 31, 2019 | -11.47M |
| Date | Value |
|---|---|
| December 31, 2018 | -10.28M |
| September 30, 2018 | -8.531M |
| June 30, 2018 | -7.196M |
| March 31, 2018 | -4.608M |
| December 31, 2017 | -2.540M |
| September 30, 2017 | -1.746M |
| June 30, 2017 | 24.44M |
| March 31, 2017 | 13.20M |
| December 31, 2016 | -0.3723M |
| September 30, 2016 | -8.551M |
| June 30, 2016 | -41.32M |
| March 31, 2016 | -37.84M |
| December 31, 2015 | -32.19M |
| September 30, 2015 | -29.56M |
| June 30, 2015 | -27.20M |
| March 31, 2015 | -23.58M |
| December 31, 2014 | -19.29M |
| September 30, 2014 | -16.84M |
| June 30, 2014 | -14.43M |
| March 31, 2014 | -15.70M |
| December 31, 2013 | -16.62M |
Free Cash Flow Range, Past 5 Years
-39.49M
Minimum
Dec 2023
-11.79M
Maximum
Jun 2019
-24.30M
Average
-23.71M
Median
Free Cash Flow Benchmarks
| Altimmune Inc | -72.76M |
| Verastem Inc | -94.50M |
| Oragenics Inc | -8.246M |
| Actinium Pharmaceuticals Inc | -39.72M |
| Orgenesis Inc | -13.05M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -6.813M |
| Cash from Investing (Quarterly) | -0.0073M |
| Cash from Financing (Quarterly) | 0.014M |
| Free Cash Flow Per Share (Quarterly) | -0.0679 |
| Free Cash Flow to Equity (Quarterly) | -6.820M |
| Free Cash Flow Yield | -75.96% |